Northridge, CA, September 07, 2007 --(PR.com
)-- Gamma Medica-Ideas Inc. (GM-I), the world leader in developing and delivering digital medical imaging devices for the pre-clinical and clinical markets, announced today three executive appointments to its Multidisciplinary Management Team. Dr. Samir Chowdhury has been named Senior Vice President and Chief Operating Officer, US Operations; Dr. Koki Yoshioka has been appointed Senior Vice President and General Manager, Norway Operations; and David Lapointe has been announced as Senior Vice President, Marketing, and General Manager, Canadian Operations.
Dr. Samir Chowdhury joined GM-I in 2005 as its Vice President. He brings expertise in the management of technology development from Siemens Medical Solutions, Nuclear Medicine Group. At Siemens, Dr. Chowdhury held the position of Senior Principal Research Scientist for five years, where he was responsible for evaluating new technology and applications for nuclear medicine (PET and SPECT), molecular imaging, computed tomography, and other medical imaging modalities. Prior to that, Dr. Chowdhury worked as the New Technology Development Manager and Senior Project Engineer at Biomec Inc. He is also a widely published author with more than 20 peer-reviewed journal articles.
Dr. Koki Yoshioka has been with the company’s Norwegian operations for twelve years, where he has assumed the role of General Manager. Previously he was Senior Vice President of Development & Engineering for GM-I after GM-I’s acquisition of IDEAS ASA (Norway), where he previously served as IDEAS Development Director. Dr. Yoshioka holds a Ph.D. in Electronic Engineering from the University of Rio de Janeiro, Brazil. While completing his Ph.D., he worked for several years at CERN – the European Organization for Nuclear Research –and is an expert in front-end electronics for particle sensors. Dr. Yoshioka is a Brazilian national and resides in Oslo, Norway.
Mr. David Lapointe co-founded Advanced Molecular Imaging (AMI) Inc. in 2003. Recently acquired by GM-I, AMI was the first company in the world to deliver a digital pre-clinical PET system. Previously, Mr. Lapointe has occupied various positions in the biomedical and pharmaceutical industry. Mr. Lapointe holds a bachelor's degree in biology and a graduate degree in Medical Imaging from the Université de Sherbrooke. He is the author of some early scientific publications demonstrating the potential of PET molecular imaging.
About Gamma Medica-Ideas, Inc.
Gamma Medica-Ideas (GM-I) designs, builds and services imaging systems based on novel technologies to improve patient health through early diagnosis of disease, improved patient treatment and by enabling new drug discovery. GM-I is dedicated to leading medical imaging into a new digital era with its unique sensor readout systems. The company’s core digital imaging technologies also hold great promise for a new class of solutions for the safety and security markets. In the pre-clinical space, GM-I’s Flex TriumphTM imaging platform is marketed for medical research and drug development. The Flex Triumph system combines PET (X-PETTM or its new fully digital LabPETTM), SPECT (X-SPECT®) and CT (X-OTM) modalities in the world’s first tri-modality system. In the clinical space, GM-I offers LumaGEM®, its dual-headed Molecular Breast Imaging (MBI) based system for early diagnosis and treatment of breast cancer. The digital gamma ray imaging technology in LumaGEM offers significant advances in resolution and contrast which has allowed for identification of millimeter sized breast cancers missed by mammography, especially in women with dense breast tissue.